Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis ($NVS) snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal. The Swiss drugmaker isn't saying much about the deal--it won't discuss the potential milestone payments that are part of the deal--but does say it plans to hustle the drug into a Phase IIb study for either diabetic neuropathy or postherpetic neuralgia, otherwise known as shingles pain. More from FierceBiotech

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.